Weekly Recap: Dupixent €25B sales forecast and Regeneron IL drug trials
Sanofi (SAN) forecasts Dupixent sales reaching €25B by 2030, having treated 1.5M patients. The company and Regeneron revised their deal to split future R&D and profits 50/50 for four IL-targeting drugs in trials by 2027.
How this was made
The 30-second read
Why it matters
The guidance is a forward‑looking estimate with minimal immediate trading impact; investors may monitor for updates as clinical data mature.
Market read
Primarily relevant to Sanofi shareholders and biotech sector analysts; limited broader market effect.
What to watch
Potential regulatory delays or market access challenges for new IL‑targeting drugs could temper growth.
Background
The article is a brief weekly recap summarizing Sanofi's Dupixent sales outlook and its revised profit‑sharing deal with Regeneron.
Ticker impact
Sanofi forecasts Dupixent sales of about €25B by 2030 and revises its profit split with Regeneron to 50/50.
likely limited pressure as investors weigh the forecast against current valuation.
Guidance is forward‑looking and not a near‑term catalyst; market may price in the forecast gradually.
Market effects
Highlights continued growth potential for the biologics/immune‑modulator sector.
European pharma outlook reinforced, modest effect on broader European markets.
Limited; primarily relevant to investors tracking Sanofi and its partnership with Regeneron.
Counterpoint
The €25B forecast may be overly optimistic given competitive pressures and pricing headwinds.
Key entities
- companySanofi
French pharmaceutical company issuing the Dupixent sales forecast.
- companyRegeneron
Partner in the IL‑targeting drug collaboration with Sanofi.
